Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
Launched by UNIVERSITY OF COLORADO, DENVER · Jul 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how adjusting oxygen levels can improve care for patients who are critically ill and on a ventilator in the ICU. The study aims to see if keeping oxygen levels between 90% and 96% can help patients breathe better, stay on the ventilator for a shorter time, and avoid low oxygen levels that can go unnoticed. Researchers believe that by educating healthcare providers about these specific oxygen targets, they can provide better care for patients with serious breathing problems.
To be eligible for this trial, patients need to be admitted to the ICU and require a ventilator to help them breathe. However, certain patients won't be included, such as those who are transferred from other hospitals, those with long-term breathing issues requiring special equipment, pregnant women, and prisoners. If someone qualifies and chooses to participate, they can expect close monitoring and guidance regarding their oxygen levels during their ICU stay. This study has not yet started recruiting participants, but it aims to enhance the treatment of respiratory failure in critically ill patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admission to ICU and requiring invasive mechanical ventilation
- Exclusion Criteria:
- * Transferred patients from outside the UCHealth system\*:
- * Patients with pre-existing disease that requires chronic use of positive pressure ventilation delivered through a tracheostomy\*:
- * Pregnant women:
- • Prisoners
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
Neil Aggarwal, MD
Principal Investigator
University of Colorado, Denver
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported